The Quinazoline Otaplimastat (SP-8203) Reduces the Hemorrhagic Transformation and Mortality Aggravated after Delayed rtPA-Induced Thrombolysis in Cerebral Ischemia

The Quinazoline Otaplimastat (SP-8203) Reduces the Hemorrhagic Transformation and Mortality Aggravated after Delayed rtPA-Induced Thrombolysis in Cerebral Ischemia

Acute ischemic stroke is the leading cause of morbidity and mortality worldwide. Recombinant tissue plasminogen activator (rtPA) is the only agent clinically approved by FDA for patients with acute ischemic stroke. However, delayed treatment of rtPA (e.g., more than 3 h after stroke onset) exacerbat...

Full description

Bibliographic Details
Main Authors: Hwa Young Song, Jee-In Chung, Angela Melinda Anthony Jalin, Chung Ju, Kisoo Pahk, Chanmin Joung, Sekwang Lee, Sejong Jin, Byoung Soo Kim, Ki Sung Lee, Jei-Man Ryu, Won-Ki Kim
Format: Article
Language:English
Published: MDPI AG 2022-01-01
Series:International Journal of Molecular Sciences
Subjects:
otaplimastat
embolic middle cerebral artery occlusion
hemorrhage
recombinant tissue plasminogen activator
matrix metalloprotease
tissue inhibitor matrix metalloproteinase
Online Access:https://www.mdpi.com/1422-0067/23/3/1403

Internet

https://www.mdpi.com/1422-0067/23/3/1403

Similar Items